Gilead Sciences Beats Q4 Views But Outlook Disappoints, Shares Fall
Gilead Sciences, Inc. (NASDAQ: GILD) shares dropped after the company beat fourth-quarter estimates but offered a forecast below expectations.
In after-hours trading, Gilead changed hands recently at $101.91, down 4.9 percent.
Gilead forecast 2015 sales between $26 billion and $27 billion, compared with Wall Street's expectation of $28.7 billion.
The maker of Sovaldi and Harvoni hepatitis C drugs also initiated a quarterly dividend at $0.43 a share starting in the second quarter, along with a $15 billion five-year buyback plan.
The new buyback is in addition to its existing $5 billion program of which $3 billion remained as of December 31.
Fourth-quarter net income was $3.5 billion, or $2.18 a share, up from $791 billion, or $0.47 a share in the year-earlier period.
Adjusted earnings were $2.43 a share, while revenue grew to $7.3 billion, from $3.1 billion last year.
Wall Street expected adjusted earnings of $2.22, on revenue of $6.72 billion.
Antiviral product sales grew nearly 160 percent in the recent quarter to $6.7 billion. The sales growth was driven by sales of Sovaldi which launched in December 2013 in the U.S. and Harvoni which launched in the U.S. in October 2014.
Other product sales, which include the hypertension drug Letairis, the angina medication Ranexa and AmBisome for meningitis increased 23 percent to $496 million for the fourth quarter.
Gilead Sciences Inc. - Earnings Surprise | FindTheBest
See more from Benzinga
Gilead Sciences Earnings Preview: Hepatitis C Guidance Is Key
Why This Analyst Thinks Gilead Sciences Will 'Handily' Beat Q4 Expectations
Gilead Sciences Just Received Orphan Drug Status For Liver Treatment
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
